Immunocore Holdings plc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
Condensed Consolidated Statements of Cash Flows
(Unaudited) (In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(27,316) | $(35,557) |
| Adjustments for: | ||
| Share-based compensation expense | 25,523 | 25,278 |
| Depreciation | 3,038 | 3,058 |
| Unrealized foreign exchange gains, net | (3,982) | (9) |
| Unrealized gains on marketable securities | (13,515) | — |
| Non-cash lease expense | 1,352 | 1,210 |
| Other | 1,535 | 197 |
| Changes in assets and liabilities: | ||
| Increase in accounts receivable | (11,053) | (7,647) |
| (Increase) decrease in prepayments and other current assets | (5,910) | 18,050 |
| Increase (decrease) in accounts payable | 1,388 | (1,130) |
| Increase in accrued expenses | 72,728 | 23,109 |
| Decrease in deferred revenue | (1) | (6,010) |
| (Decrease) increase in operating lease liabilities | (1,208) | 645 |
| Increase in other operating assets | (4,515) | (2,676) |
| Increase in other operating liabilities | 1,948 | 2,155 |
| Net cash provided by operating activities | 40,012 | 20,673 |
| Cash flows from investing activities | ||
| Purchase of marketable securities | (350,000) | — |
| Purchase of property and equipment | (1,589) | (4,608) |
| Net cash used in investing activities | (351,589) | (4,608) |
| Cash flows from financing activities | ||
| Proceeds from issue of convertible senior notes | 402,500 | — |
| Payments for debt issuance costs | (13,358) | — |
| Proceeds from exercise of share options | 6,250 | 28,092 |
| Net cash provided by financing activities | 395,392 | 28,092 |
| Increase in net cash and cash equivalents | 83,815 | 44,157 |
| Net foreign exchange difference on cash held | 11,326 | (2,491) |
| Cash and cash equivalents at beginning of period | 442,626 | 402,472 |
| Cash and cash equivalents at end of period | $537,767 | $444,138 |
| Supplemental disclosure of cash flow and non-cash information | ||
| Cash received for interest, net | $7,285 | $5,703 |
| Cash paid for income taxes, net | $(352) | $(220) |
| Purchases of property and equipment in accounts payable | $840 | $65 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.